Rigel launches Phase II trial to assess fostamatinib for Covid-19
Simplified schema of ITP pathogenesis showing the sites of action of... | Download Scientific Diagram
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia | Immunotherapy
JCM | Free Full-Text | Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion - Alessandro Lucchesi, Bruno Fattizzo, Valerio De Stefano, Marco Ruggeri, Sergio Siragusa, Nicola Vianelli, Francesco
Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406 | SpringerLink
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
Mechanism of Action | TAVALISSE HCP
Frontiers | Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?
Evolution of CLL treatment — from chemoimmunotherapy to targeted and individualized therapy | Nature Reviews Clinical Oncology
Autoimmune thrombocytopenia: Current treatment options in adults with a focus on novel drugs
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
COVID-19 :: Rigel Pharmaceuticals, Inc. (RIGL)
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib - Nichola Cooper, Ivy Altomare, Mark R. Thomas, Phillip L. R. Nicolson, Steve P. Watson, Vadim Markovtsov, Leslie K. Todd,
Mechanism of action: R406 is a Syk kinase inhibitor. a, inhibition of... | Download Scientific Diagram
Fostamatinib: A Review in Chronic Immune Thrombocytopenia | SpringerLink
![PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5c2330a7e20affaf506ba421407aa70a9a225a24/5-Figure1-1.png "PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar")
PDF] Efficacy and mechanism of intravenous immunoglobulin treatment for immune thrombocytopenia in adults | Semantic Scholar
g176401moi008.gif
APS Publications on Twitter: "Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology - new Review in @AJPCellPhys https://t.co/G9SSGG4Hrq #platelets #articlesinpress https://t.co/oJ0JnJMjho" / Twitter
Fostamatinib for persistent/chronic adult immune thrombocytopenia | Immunotherapy
Thrombopoietin receptor agonists: ten years later | Haematologica
Advances in targeted therapy for malignant lymphoma | Signal Transduction and Targeted Therapy
Rigel's fostamatinib successfully meets endpoint in chronic ITP trial
